Biomimetic nanotechnology toward personalized vaccines

Summary

This review considers biomimetic nanotechnology as a route to more personalized antibacterial and anticancer vaccines. It begins from two clinical pressures: multidrug-resistant pathogens increasingly escape standard antibiotics, while tumor diversity has undermined the idea of a universal anticancer treatment. Vaccination could help both prevention and therapy, but existing formulations may lack potency or represent too narrow a set of antigens. The article surveys recent biomimetic nanovaccines designed to address those limitations. Such platforms can reproduce selected biological interfaces, carry complex antigen mixtures, and organize immune-stimulatory functions within an engineered nanoscale construct. The review emphasizes personalization, meaning that vaccine composition or biological source can be matched to the pathogen, tumor, or individual rather than fixed for every recipient. Its principal synthesis is that biomimetic materials may improve both immune strength and antigenic breadth, two requirements that conventional formulations do not always satisfy together. The significance is a shared engineering framework for difficult bacterial infections and heterogeneous cancers. Because the article is a review, the abstract does not establish patient benefit, define how personalization would be manufactured or regulated, compare platform safety, or show that broader antigen presentation consistently produces better outcomes.